Fundraising Fox
🦊/People
Sign in

Jeffrey M. Jonas

Investor

Partner at Cure Ventures · Board director at RYNE Biotechnology Inc. · Executive at Sage Therapeutics

Boston, Massachusetts, United States

Find your path to Jeffrey

363 people in our graph share verified history with Jeffrey — schools, employers, funds. One of them is your warm intro.

Will ReedunlockedJeffrey: together at Amherst College
×10Jeffrey: together at Amherst College
Jeffrey: together at Sage Therapeutics

About

Partner with over two decades in CNS drug discovery and development, contributing to medicines such as Lexapro, Vyvanse and Zulresso. Previously CEO of ABIO-X and CEO/Chief Innovation Officer at Sage Therapeutics.

Contact· self-published, not guessed

Board director at RYNE Biotechnology Inc.

Intro paths

→

In turn, Jeffrey can intro founders to RYNE Biotechnology Inc.'s investors below.

RYNE Biotechnology Inc.'s investors · 2

Cure VenturesBoston · since 2024The Column GroupSan Francisco · $30M checks · since 2024

Executive at Sage Therapeutics

Intro paths

→

In turn, Jeffrey can intro founders to Sage Therapeutics's investors below.

Sage Therapeutics's investors · 2

ARCH Venture PartnersChicago · $50K – $250M checksThird Rock VenturesBoston · $100K – $5M checks · since 2020

Experience

  1. Tortugas NeuroscieceChief Executive Officercurrent2026 — presentMassachusetts, United States
  2. Compass PathwaysDirectorcurrent2025 — presentUnited Kingdom
  3. Kenai TherapeuticsChairmancurrent2024 — presentUnited States
  4. Cure VenturesPartnercurrent2024 — present
  5. Noema PharmaChairman of the Boardcurrent2021 — present
  6. Karuna TherapeuticsDirector2015 — 2024
  7. Generation BioDirector2016 — 2024
  8. Sage TherapeuticsDirector2013 — 2023
  9. Sage TherapeuticsChief Executive Officer2013 — 2020Greater Boston Area
  10. ABio-XChief Executive Officer2022 — 2023
  11. Shire PharmaceuticalsPresident Shire Regenerative Medicine2012 — 2013
  12. Shire PharmaceuticalsSenior Vice President R&D - Specialty Pharma and Regenerative Medicine2011 — 2012
  13. Shire PharmaceuticalsSenior Vice President Research and Development2008 — 2011
  14. Isis PharmaceuticalsEVP2007 — 2008
  15. Forest LaboratoriesEVP/CMO2002 — 2007
  16. UpjohnChief Medical Officer/ VP Clinical Development1991 — 1996

Skills & more

IND2Clinical Development91Drug Development68Pharmaceutical Industry50Biotechnology44Clinical Trials38R&D37Biopharmaceuticals37Oncology21Neurology20Drug Discovery18Regulatory Affairs15
+12 moreClinical ResearchRegulatory SubmissionsLifesciencesMedical DevicesFDACROInfectious DiseasesCross-functional Team LeadershipRegenerative MedicineCTMSNeuroscienceImmunology

From Jeffrey's professional profile.

Colleagues at Cure Ventures

Albert J. Robichaud
Partner at Cure Ventures
Annie Mitsak
Partner at Cure Ventures
Bill Amsbaugh
CTO and Partner at Cure Ventures
Courtney Turner
Director of Finance at Cure Ventures
David Fallace
Managing Partner at Cure Ventures
Dr. Michael Aberman
Investor at Cure Ventures
Dr. Milenko Cicmil
Investor at Cure Ventures
Drew King
CFO and Partner at Cure Ventures

Frequently asked questions

Who is Jeffrey M. Jonas?
Partner with over two decades in CNS drug discovery and development, contributing to medicines such as Lexapro, Vyvanse and Zulresso. Previously CEO of ABIO-X and CEO/Chief Innovation Officer at Sage Therapeutics.
Where does Jeffrey M. Jonas work?
Jeffrey M. Jonas is Partner at Cure Ventures and Board director at RYNE Biotechnology Inc. and Executive at Sage Therapeutics.
Where did Jeffrey M. Jonas go to school?
Jeffrey M. Jonas studied at Harvard Medical School (MD); Amherst College (BA, Biology/English); Harvard Medical School.

Founder mafias

RYNE Biotechnology Inc. mafia2

Also came through, then founded or led a company.

Jeff GoaterDirectorFounded Atavistik Bio

Same school

Shared employers